KR102086150B1 - in situ Hydrogel Forming Powder Composition for Wound Healing, and Method for Preparing thereof - Google Patents

Abstract

The present invention relates to a powder composition for wound treatment comprising S-nitrosoglutathione (GSNO), alginate salt, pectin and polyethylene glycol (PEG) as an active ingredient, and a method for preparing the same. The composition according to the present invention is used in combination with an alginate-based in situ hydrogel forming system with appropriate drug release control ability and GSNO to enhance formulation stability when stored with both powder and film advantages, and to be applied to the wound site. It can quickly turn into a gel to cover the wound or provide a hydration environment, and can effectively remove the bacteria present in the exudative wound and promote wound healing through promoting cell differentiation and collagen synthesis.

Description

Hydrogelized powder composition for wound healing and preparation method thereof {in situ Hydrogel Forming Powder Composition for Wound Healing, and Method for Preparing}

The present invention relates to a powder composition for treating wounds that is hydrogelized when applied to a wound and a method for preparing the wound.

The skin that surrounds our bodies is exposed to many dangerous physical damages in our daily lives. Therefore, many factors around us, such as mechanical damage, bruises, burns of the skin, wounds occur. A wound is a state in which the anatomical continuity of a human tissue has lost its original continuity by external action. For example, our skin is composed of epidermis, dermis, and subcutaneous fat. The wound that loses continuity such as epidermis, dermis, and subcutaneous fat by trauma such as cut or falling is called wound.

In general, dressing is used to effectively treat skin wounds such as wounds and traumas. Wound dressings have the following characteristics: proper moisture retention in contact with wounds, ability to control wound discharge, ease of attachment and removal of dressings to wounds, air and vapor permeability between external wounds, external Insulation of wounds, resistance to bacterial invasion, non-toxicity to human body, good mechanical properties, etc. are required.

Currently, the most popular wound healing methods are ointment. The most popular products for promoting skin wound healing include Madecassol (Dongkuk), Sentica (Samjin Pharm) and Tinadex (Chong Kun Dang).

Nitric oxide releasing films containing S-nitrosoglutathione (GSGS), a nitric oxide donor that spontaneously forms in the human body, not only have mechanical properties that can be applied to the human body, but also gradually oxidize The film can be useful for wound healing because it releases nitrogen and suppresses pathogens that are the main cause of wound infections and can quickly heal wounds.

However, due to the nature of the film formulation, there is a limit to apply to the exudation wounds, a wide range of wounds or wounds of many body parts. In addition, due to problems in the manufacturing process there is a limit that can not ensure the stability of the GSNO in the storage conditions, such as refrigeration, room temperature other than -20 ℃.

In addition, in the case of a wound of a large area or a large portion of the wound, a hydrogel-type formulation may be more useful than a film-type formulation. However, most nitric oxide donors including S-nitrosoglutathione have a high moisture content. Since it is unstable and rapidly decomposed in an environment, there is a problem that it is very difficult to ensure the stability of the formulation to be formulated into a film. On the other hand, the powder is excellent in stability, but can not provide a wet environment of the wound site, there is a problem that it is difficult to maintain a concentration that can maintain a therapeutic effect for a long time because the release pattern of NO also rapidly made.

Korean Patent Registration No. 10-0445146 (registered Aug. 10, 2004).

It is an object of the present invention to hydrogelize nitric oxide donor S-nitrosoglutathione (S-Nitrosoglutathione), which has an effect of promoting wound healing and antibacterial effect, so that exudates from the wound can be absorbed and quickly changed into a gel form. To provide a powder composition for wound treatment.

Another object of the present invention is to provide a method for preparing a powder composition for wound treatment that is hydrogelized rapidly upon application of wound.

In order to achieve the above object, the present invention provides a powder composition for wound treatment containing S-nitrosoglutathione (GSNO), alginate salt, pectin and polyethylene glycol (PEG) as an active ingredient do.

In order to achieve the above another object, the present invention comprises the steps of (1) grinding each of the powder form of GSNO, alginate salt, pectin and PEG; (2) mixing all the pulverized products prepared in step (1); And (3) passing the mixture prepared in step (2) through a sieve.

The present invention relates to a powder composition for treating wounds and a method for producing the same which is hydrogelized when applied to a wound, and the powder composition of the present invention can be hydrogelized to effectively treat a wound area having a larger area than a film-type preparation. The exudates such as bedsores and burns are more susceptible to infections and have wider potential for wounds than conventional commercialized products. In addition, the manufacturing process is simple and easy for mass production, and is also stable at room temperature when stored in a sealed container.

Figure 1 shows the water absorption of the nitric oxide-containing wound treatment powder composition to be hydrogelated when applying the wound of the present invention and the resulting morphological changes.
Figure 2 shows the storage stability of the powder composition of the present invention.
3 is a result of the NO release experiment according to the moisture absorption of the powder composition of the present invention.
4 is a result of an in vitro antibacterial test of the powder composition of the present invention.
5 is a result of the antimicrobial performance test using a confocal laser fluorescence microscopy of the powder composition of the present invention.
6 is Pseudomonas Pseudomonas of the powder composition of the present invention aeruginosa ) shows wound healing test results in an infected animal model.
Figure 7 shows the results of the quantification of bacteria in the wound in the in vivo animal model.
FIG. 8 shows the results of Wort's gram staining on the wound surface at 14 days after the start of treatment (normal skin (A), untreated group (B, C), powder carrier treated group (D) , Powder composition treatment group (E) of the present invention).
Figure 9 shows a comparison of the degree of tissue recovery through histological staining (A, B, C, D is H & E staining, E, F, G, H is a Masson's trichrome staining technique, A , E is a normal tissue, B, F is an untreated group, C, G is a group treated only with a powder carrier, D, H is a group treated with the powder composition of the present invention E: epidermis, F: fiber Fibrous tissue G: granulation tissue, H: hair follicle, I: immune cells, M: muscle).
10 is a result of confirming the uniformity of the GSNO content of the composition powder prepared by the production method including and without the grinding process.
11 is a result of comparing the therapeutic effect of the content of the alginate salt in the composition powder of the present invention.
12 shows the results of gelation formation experiments according to the presence of pectin and PEG in the composition powder of the present invention.

Hereinafter, the present invention will be described in more detail.

When the inventors of the present invention are based on GSNO and alginate salts, the wound healing effect is excellent and the antibacterial effect can be effectively converted into gel form by absorbing the exudates at the wound site, which is why the present invention is more effective than the film type preparation. The present invention has been completed by discovering that powder formulations may be useful for treating large areas of wounds.

Therefore, the present invention provides a powder composition for wound treatment comprising S-nitrosoglutathione (S-Nitrosoglutathione; GSNO), alginate salt, pectin and polyethylene glycol (PEG) as an active ingredient.

According to the present invention, alginate is used as a gelling agent, so that the nitric oxide donor GSNO, which has a wound healing promoting effect and an antibacterial effect, can absorb the exudates at the wound site and quickly change into a gel form, thereby forming hydrogel in in situ. It is possible.

GSNO, the main active ingredient in the powder composition, is a nitric oxide donor that is also present in the body and is involved in cell differentiation, collagen synthesis, and the like by nitric oxide (NO) generated during decomposition, thereby promoting and helping to recover from a wound. In addition, the oxidative stress caused by the nitric oxide generated has an antimicrobial effect, and this mechanism is hardly resistant to resistance and exhibits an antimicrobial effect without a gram negative / positive distinction, so it is suitable for use in skin wound infection.

In one embodiment of the present invention, based on 100 parts by weight of the powder composition, 2 parts by weight of GSNO to 10 parts by weight, 10 parts to 40 parts by weight of alginate salt, 5 parts to 20 parts by weight of pectin and 50 parts by weight to PEG When included in the numerical range, it can be included in 80 parts by weight, it is preferable because the modification to the uniform and durable gel at the wound site is made quickly, and the wound healing effect is maximized.

More preferably, the GSNO: alginate salt: pectin: PEG may be included in a weight ratio of 4: 21: 11: 64.

The powder composition may be modified in a hydrogel form within 1 to 3 minutes at the wound site, the powder composition according to the present invention solves the problems appearing in the powder form or film form, all of the advantages of each form Can be represented.

In particular, the powder composition is used to treat wounds by slowly releasing nitric oxide (NO) from the wound site, or to any one or more of Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus (MRSA). The wound composition can be treated by exhibiting antimicrobial activity against the bar. In one embodiment of the present invention, the powder composition of the present invention has improved sustained release of nitric oxide, and is also the most problematic Gram-positive bacteria among hospital infections, MRSA. And Gram-negative bacteria P. aeruginosa It was verified that the bactericidal effect of 99.99% or more against two species of.

The wound may be any one or more selected from abrasions, lacerations, burns, cuts, cuts, crystallizations, penetrating wounds, and left wounds, but is not limited thereto.

Moreover, the present invention comprises the steps of (1) milling GSNO, alginate salt, pectin and PEG in powder form, respectively; (2) mixing all the pulverized products prepared in step (1); And (3) passing the mixture prepared in step (2) through a sieve.

In the steps (1) to (3), based on 100 parts by weight of the powder composition, 2 parts by weight of GSNO to 10 parts by weight, 10 parts to 40 parts by weight of alginate salt, 5 parts to 20 parts by weight of pectin and PEG 50 It may be included in the weight part to 80 parts by weight, when it is included in the range produced when the modification to the uniform and durable gel at the wound site is made quickly, and also a powder composition that maximizes the wound healing effect can be prepared.

In the step (3), the sieve may be a porous structure having an average diameter of 80 ㎛ to 100 ㎛, but is not limited thereto.

More specifically, in the step (3), the prepared wound treatment powder composition may include GSNO: alginate salt: pectin: PEG in a weight ratio of 4: 21: 11: 64.

Hereinafter, examples will be described in detail to help understand the present invention. However, the following examples are provided to more fully explain the present invention to those skilled in the art, and are merely illustrative of the contents of the present invention, the scope of the present invention is limited to the following examples no.

< Example  1> Preparation of the powder composition for wound treatment according to the present invention

In order to prepare a wound care powder composition according to the present invention, GSNO, sodium alginate, pectin and PEG (MW: 8000) were first ground to a standard No. 170 (average diameter of the hole is 90 μm). Thereafter, GSNO: alginate salt: pectin: PEG was mixed in a weight ratio of 4: 21: 11: 64, and then passed through No. 170 to prepare a powder composition for wound treatment according to the present invention. As a control, a gelling powder (Comparative Example 1) prepared by mixing GSNO, sodium alginate, pectin and PEG (MW: 8000) without grinding in the same weight ratio was used. And sodium alginate: pectin: PEG were prepared by mixing in a weight ratio of 2: 1: 6.

Experimental Example 1 Water Absorption and Shape Change Analysis

For the powder composition prepared in Example 1, the change in form with time through the moisture absorption experiment was confirmed. Specifically, the in vitro test method was as follows: First, the cellulose membrane was contacted on a simulated wound fluid (SWF) mimicking the wound exudate, and then 40 mg of the powder composition prepared in Example 1 was added to cellulose. Evenly distributed over the membrane. At this time, since the water molecules are diffused over the cellulose membrane and absorbed in the powder composition, the photographs were taken every designated time, and the weight of the absorbed fluid (exudate) was measured.

In vivo experimental methods were also as follows: 7 weeks old ICR mice were anesthetized and the dorsal hairs were removed and full layer wounds were generated with an 8 mm biopsy punch. After spraying evenly 40 mg of the powder composition prepared in Example 1 on it was taken pictures according to the specified time.

As a result, as shown in Figure 1, it was confirmed that the powder composition prepared in Example 1 has the ability to absorb up to 350% moisture and quickly change to a gel form (Fig. 1 (A): in vitro Figure 1 (B): Changes in the state of the powder when the powder was treated to a full thickness excision wound in an in vivo mouse model. 1 (C): measuring the water absorption capacity of the powder).

Experimental Example 2 Storage Stability Analysis

For the powder composition prepared in Example 1, storage stability was analyzed. The specific experimental method was as follows: The powder composition prepared in Example 1 was placed in a microtube by 10 mg each and then placed in a 4 ° C. refrigerator and 37 ° C. incubator. Thereafter, three microtubes were taken out at regular intervals, dissolved in water, and the absorbance at 335 nm was measured using an ultraviolet visible absorbance spectrometer to quantify and compare the amount of GSNO.

As a result, as shown in Figure 2, for 140 days, even at 4 ℃ and 37 ℃ storage conditions it was confirmed that no significant degradation of the GSNO of the powder composition was observed, in view of this point, It was found that storage is possible without fear of decomposition of the drug.

Experimental Example 3 Analysis of NO Release According to Water Absorption of GNSO

With respect to the powder composition prepared in Example 1, the amount of GNSO released according to the degree of moisture absorption was confirmed. Specifically, the following experimental method was carried out: 50 mg of the powder composition prepared in Example 1 was uniformly dispersed on the bottom of a 2 ml microtube having a flat bottom surface, and then absorbed less exudate (200% absorption). ), The most absorbed state (350%) and the amount of SWF that would have been exposed to more exudates than the absorbable amount (500%) was added to each tube. Thereafter, three microtubes were taken in a 37 ° C. incubator every time, dissolved in water, and the remaining amount of GSNO was measured and analyzed using an ultraviolet-visible spectrophotometer.

As a result, as shown in FIG. 3, when the powder is exposed to a small amount of moisture, when exposed to a large amount of moisture, the NO emission pattern is observed for 24 hours or more under all conditions when the powder is in a moisture environment above the maximum absorption point. Indicated.

Experimental Example 4 in vitro antibacterial test

The powder composition prepared in Example 1 was subjected to antibacterial experiments in vitro. Specifically, the following experimental method was carried out: P. aeruginosa (PAO1, purchased from KCTC) and MRSA (USA 300, purchased from ATCC) were incubated for 12 hours, and then the maximum absorption amount was prepared in Example 1 10 ⁸ CFU / ml of bacteria were added to the powder composition and incubated for 24 hours, CFU was measured and compared and analyzed. In addition, the bacterium exposed to the powder composition prepared in Example 1 was exposed for 24 hours using a Baclight live / dead kit, and photographed with a confocal laser fluorescence microscope.

As a result, as shown in Figure 4, it was confirmed that more than 99.99% bacteria were reduced in both treatment with P. aeruginosa and MRSA in vitro.

In addition, as shown in FIG. 5, almost all of the dots appeared red in the group treated with the composition, indicating that most of the bacteria were killed (green fluorescence indicates living bacteria and red fluorescence indicates dead bacteria). .

Experimental Example 5 Wound Recovery Capability Test Analysis

With respect to the powder composition prepared in Example 1, the wound recovery ability was confirmed in the bacterial infection ICR mouse model. Specifically, the following experimental methods were performed: 6-week-old ICR mice were purchased, acclimated for 1 week, anesthetized, and fur was removed. Whole layer wounds were created using 8 mm biopsy punches on the back, and 10 ⁹ CFU of P. aeruginosa was added to each wound and the wounds were sealed and left for 2 days to make infected whole layer wounds. Thereafter, every two days, the powder composition prepared in Example 1, the powder composition without GSNO (powder carrier), and the untreated group were divided into three groups, and photographs were taken each time to compare and analyze the size. It was.

As a result, as shown in Figure 6, it was confirmed that the size of the wound significantly decreased with time, the powder-treated group is significantly superior to the non-treated group or the group containing only the powder carrier (carrier) Size reduction effect was shown.

Experimental Example 6 In vivo Bacterial Determination and Gram Staining of Twort

For the powder composition prepared in Example 1, the number of bacteria in the wound in the mouse model was quantified. At this time, the following experimental method was performed: 6 weeks old ICR mice were purchased, acclimated for 1 week, anesthetized, and hair was removed. Whole layer wounds were created using 8 mm biopsy punches on the back, and 10 ⁹ CFU of P. aeruginosa was added to each wound and the wounds were sealed and left for 2 days to make infected whole layer wounds. Thereafter, the powder composition prepared in Example 1 and the powder composition without GSNO (powder carrier) were divided into a total of three groups of non-treated groups, and euthanized three mice on a predetermined date to tear off wounds. Finely pulverized and diluted, only P. aeruginosa was incubated in a selectively grown cetrimide medium, and CFU was measured.

In addition, Gram staining of Twort was performed as follows: On the 14th day of the last day of the experiment, animals were euthanized and wounds were harvested to make paraffin blocks and preserved. The block was cut to a thickness of 5 um and pasted onto a slide glass and dried in an oven at 37 ° C. for 12 hours. Paraffin was removed using xylene, and 100% ethanol and 95% ethanol were added thereto, and washed with distilled water. After primary dyeing with crystal violet, secondary dyeing with natural red and fast green solution, the mounting medium was covered with xylene and then covered with a cover glass. Finally, P. aeruginosa , which is about 1 um in length, was observed and photographed at a magnification of 1000 times using an optical microscope.

As a result, as shown in Figure 7, P. aeruginosa When the amount of bacteria in the wound was measured in the infected ICR mouse model, the amount of bacteria in the powder composition treatment group was significantly reduced, indicating that the powder composition according to the present invention can effectively remove the bacteria in the wound area. Proved.

In addition, as shown in FIG. 8 showing the results of Wort's gram staining on the wound surface at the point of day 14 after the start of treatment, the wound was observed histologically on the day 14 after the start of treatment. P. aeruginosa Tissue staining techniques to visualize the presence of bacteria showed that a large number of bacteria could be visually observed in the untreated group, but in the group treated with the powder composition, only a small number of bacteria were present that could not be detected. Normal skin (A), untreated group (B, C), powder carrier treated group (D), powder composition (E) treated group of the present invention).

Experimental Example 7 Analysis of Tissue Recovery

Hematoxylin & Eosin staining (H & E staining) and Mason's trichrome staining technique (masson's trichrome staining) to confirm the amount of collagen for the powder composition prepared in Example 1 Was performed. Specifically, the method was performed as follows: On the 14th day of the last day of the experiment, the animals were euthanized and the wounds were collected and preserved by making paraffin blocks. It was then cut to a thickness of 5 um, pasted onto a slide glass and dried in an oven at 37 ° C. for 12 hours. Paraffin was removed using xylene, and 100% ethanol and 95% ethanol were added, respectively, and washed with distilled water. In the case of H & E staining, hematoxylin and eosin were stained in turn, and in the case of Mason's trichrome staining, staining was performed according to the dyeing procedure provided by ABCAM. Thereafter, tissues were compared, observed and photographed at a magnification of 200 times using an optical microscope.

As a result, referring to Figures 9A to D, when the powder composition was treated, it was found that the recovery was better to a degree closer to normal tissue than the non-treated group or the group treated only with the powder carrier. In addition, referring to Figures 9E to 9H, the amount of collagen was observed in the group treated with the powder composition compared to the other two groups.

Experimental Example 8 Comparison of Powder Particle Characteristics According to Experimental Method

Content uniformity was confirmed for the powder composition prepared in Example 1 and Comparative Example 1 prepared without undergoing a grinding process. That is, each powder was unfolded and randomly sampled at 10 places to measure the content of GSNO. At this time, the weight of the powder of about 10 mg was measured and dissolved in water, and the absorbance at 335 nm by using an ultraviolet visible spectrophotometer to measure and compare the content of GSNO. In addition, the Hausner ratio calculated | required tap density and bulk density, and calculated it by these ratios.

As a result, as shown in FIG. 10, the powder composition of Example 1, which was subjected to the grinding process, was found to have a more uniform distribution of GNSO, thereby preparing a formulation with high uniformity. Since the fluidity is lowered at, it was confirmed that when applied to the actual wound it can further reduce the phenomenon of the powder flowing down before it turns into a gel.

Experimental Example 9 Gel Formation Time Comparison with Other Gelling Agents

Powder carrier compositions containing various gelling agents were prepared in the same manner as in Example 1 except that GSNO was not mixed in order to determine whether the gelling ability was different when using other gelling agents instead of alginate. . Specifically, hyaluronic acid, carrageenan, poloxamer, gelatin, guar gum, CMC-Na or chitosan are used instead of alginate as a gelling agent, respectively. To prepare Comparative Example 2 to 8 powder carrier composition. At this time, the content ratio of each composition was the same as the excipient ratio except the GSNO of the powder composition of Example 1, the gelling agent: pectin: PEG = 2: 1: 6.

Thereafter, 10 mg of each composition was placed in a flat bottom 2 ml tube, and 100 μl of PBS was dropped, and the time of gelation was measured. At this time, as a time point to become a gel, the gel generated when the tube was flipped over and lightly knocked was based on the time point when the gel was attached to the tube without falling down for 5 seconds or more.

As a result, in order to use as an in situ hydrogel-forming powder, the ability of rapid gel formation within 3 minutes is essential. Referring to Table 1 below, the gelling agent except for alginate and hyaluronic acid is 10 minutes until gel formation. Since the above has passed, it can be seen that it is not suitable as a gelling agent of the in situ hydrogel-forming powder. In other words, alginate and hyaluronic acid showed in situ hydrogel formation, but hyaluronic acid showed a slower gelation rate than alginate, and thus, alginate was the most optimal gelling agent for rapid gel formation.

Experimental Example 10 Comparison of Treatment Effect According to Alginate Content

In order to check whether there is a therapeutic effect even when a low concentration of alginate is included, a powder composition is prepared according to the method described in Example 1, but the alginate content is 10% (relative to the total weight), and the effect is verified. A powder containing 2% GSNO and a powder containing 10% GSNO, were prepared. In this case, as the content ratio, GSNO: alginate salt: pectin: PEG was prepared to be 2: 10: 5: 83 and 10: 10: 5: 75. And to determine the effect of the high concentration of alginate on the actual wound, a powder containing 40% alginate was prepared (GSNO: alginate salt: pectin: PEG: 4: 40: 20: 36), and in Example 1 The mouse animal model was treated in the same manner as the prepared powder composition.

At this time, the specific experimental method was as follows: 6-week-old ICR mice were purchased and adapted for 1 week, followed by anesthesia and hair removal. Whole layer wounds were made using 8 mm biopsy punches on the back, and the drug was treated into the above-mentioned drug and GSNO-free carrier powder composition, and the non-treated group, and the drugs were treated and photographed every 2 days for comparison and analysis. .

As a result, referring to FIG. 11A, in the case of the composition powder using a low content of alginate (2% and 10%) of less than 15%, the exudates did not properly absorb the gel, and GSNO was easily removed. In particular, mice were treated with no significant therapeutic effect. On the other hand, referring to Figure 11b, the powder composition comprising 15 to 30% of the alginate absorbed the exudate and continuously released NO while maintaining the gel form, especially in the mouse model showed a significant therapeutic effect. In addition, referring to FIG. 11C, when the alginate is included in an excessively high proportion (greater than 30%), absorption is so high that the wound is dried and the dressing is strongly entangled in the wound, which is difficult to use in general wounds. It was judged that.

Experimental Example 11 Role-Checking Experiments of Pectin and PEG

In order to confirm the role of pectin and PEG, alginate was fixed at 22 parts by weight and experimented by changing the amount of pectin and PEG. That is, when the powder composition is prepared according to the preparation method disclosed in Example 1, but contains only 22 parts by weight of alginate and 77 parts by weight of pectin (alginate: pectin = 2: 7 weight ratio) (A), and 22 parts by weight of alginate and Only 77 parts by weight of PEG (alginate: PEG = 2: 7 weight ratio) and 22 parts by weight of alginate and 11 parts by weight of pectin and 66 parts by weight of PEG (alginate: peptine: PEG = 2: 1: 6 weight ratio ) Was prepared in each case of the powder (C), and then gel formation experiments were performed. The specific method was as follows: Each powder prepared was spread evenly by 50 mg in a small dish, and then the shape of the gel formed by evenly adding 1 ml of distilled water was observed and photographed.

As a result, as shown in Figure 12, when there is no PEG (A), the powder particles are entangled with each other to form a gel having a high viscosity only in the portion where the powder is sprayed, there is no pectin (B), uniform One gel was formed but the strength of the gel was weak, and it was confirmed that the time until the gel did not flow completely took longer than that with pectin. As in Example 1 of the present invention, when all of the alginate, pectin, PEG is included (C), it was confirmed that the gel is formed quickly and uniformly.

From these experimental results, it was found that excess pectin or PEG was not good for the formation of a uniform and durable gel, and a formulation containing 5 to 20 parts by weight of pectin and 50 to 80 parts by weight of PEG was suitable as an in situ hydrogel forming powder. Could know.

Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that such a specific description is merely a preferred embodiment, thereby not limiting the scope of the present invention. Do. In other words, the substantial scope of the present invention is defined by the appended claims and their equivalents.

Claims (10)

S-nitrosoglutathione (S-Nitrosoglutathione; GSNO), alginate salt, pectin and polyethylene glycol (PEG) as an active ingredient,
The GSNO: alginate salt: pectin: PEG is a powder composition for wound treatment, characterized in that included in a weight ratio of 4: 21: 11: 64. According to claim 1, wherein the powder composition based on 100 parts by weight of GSNO 2 to 10 parts by weight, 10 to 40 parts by weight of alginate salt, 5 to 20 parts by weight of pectin and 50 to 80 parts by weight PEG Powder composition for wound treatment, characterized in that it is included as a part. delete The method of claim 1, wherein the powder composition is a wound wound powder composition, characterized in that denatured in hydrogel form within 1 to 3 minutes at the wound site. The method of claim 1, wherein the powder composition is wound treatment powder composition, characterized in that for treating the wound by releasing nitric oxide (NO) at the wound site. The method of claim 1, wherein the powder composition is Pseudomonas Aeruginosa ) or methicillin-resistant Staphylococcus aureus (W) shows a antimicrobial activity against any one or more bacteria, wound powder composition for the treatment of wounds, characterized in that. The method of claim 1, wherein the wound is a wound, a wound, a burn, a cut, a cut, a cut out, a penetrating wound and a wound wound, characterized in that any one or more selected from the powder composition. (1) grinding GSNO, alginate salt, pectin and PEG in powder form, respectively;
(2) mixing all the pulverized products prepared in step (1); And
(3) passing the mixture prepared in step (2) through a sieve,
In the step (3), the prepared wound composition powder composition comprises GSNO: alginate salt: pectin: PEG in the weight ratio of 4: 21: 11: 64. The method according to claim 8, wherein in the steps (1) to (3), based on 100 parts by weight of the powder composition, 2 parts by weight to 10 parts by weight of GSNO, 10 parts by weight to 40 parts by weight of alginate salt, 5 parts by weight to pectin 20 parts by weight and 50 parts by weight to 80 parts by weight of PEG for the preparation of a powder composition for treating wounds. delete

Images